In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d

Behnood Bikdeli; David A Garcia

doi:10.7326/J21-0019

In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d

Ann Intern Med. 2022 Feb;175(2):JC17. doi: 10.7326/J21-0019. Epub 2022 Feb 1.

Authors

Behnood Bikdeli¹, David A Garcia²

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA (B.B.).
² University of Washington, Seattle, Washington, USA (D.A.G.).

PMID: 35099994
DOI: 10.7326/J21-0019

Abstract

Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181:1612-20. 34617959.

Publication types

Comment

MeSH terms

Anticoagulants / adverse effects
COVID-19*
Heparin / adverse effects
Humans
Inpatients
SARS-CoV-2
Venous Thromboembolism* / chemically induced

Substances

Anticoagulants
Heparin